BeOne Medicines (ONC) Non-Current Debt (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Non-Current Debt data on file, last reported at $962.5 million in Q1 2026.

• Quarterly Non-Current Debt rose 500.98% year-over-year to $962.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $962.5 million (up 500.98% YoY) and the FY2025 annual result came in at $961.9 million, up 477.78% from the prior year.
• Non-Current Debt steadied at $962.5 million in Q1 2026 per ONC's latest filing, from $961.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $962.5 million in Q1 2026 and bottomed at $146.1 million in Q2 2025.
• The 5-year median for Non-Current Debt is $201.6 million (2022), against an average of $318.8 million.
• The widest annual swing landed in 2025, when Non-Current Debt fell 21.15%; it then jumped 500.98% in 2026.
• Tracing ONC's Non-Current Debt over 5 years: stood at $209.1 million in 2022, then fell by 5.51% to $197.6 million in 2023, then declined by 15.75% to $166.5 million in 2024, then soared by 477.78% to $961.9 million in 2025, then increased by 0.06% to $962.5 million in 2026.
• Per Business Quant, the three latest ONC Non-Current Debt figures stand at $962.5 million (Q1 2026), $961.9 million (Q4 2025), and $832.8 million (Q3 2025).

Peer Comparison